Research programme: androgen-based therapeutics - CPEX

Drug Profile

Research programme: androgen-based therapeutics - CPEX

Latest Information Update: 14 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bentley Pharmaceuticals; Dartmouth College; Dartmouth Medical School
  • Developer CPEX Pharmaceuticals; Dartmouth College; Dartmouth Medical School
  • Class Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic fatigue syndrome; Fibromyalgia; Male osteoporosis

Most Recent Events

  • 06 Aug 2009 No development reported - Clinical-Phase-Unknown for Fibromyalgia in USA (Topical)
  • 23 Jul 2008 Bentley Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 25 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top